Tenax Therapeutics Inc TENX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TENX is a good fit for your portfolio.
News
-
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
-
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
-
Tenax Therapeutics to Present at the 36th Annual Roth Conference
-
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
-
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
-
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
-
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
-
Thinking about buying stock in McDonald's, Uber Technologies, Medavail, Intelligent Bio Solutions, or Tenax Therapeutics?
Trading Information
- Previous Close Price
- $3.68
- Day Range
- $3.57–3.78
- 52-Week Range
- $3.48–61.20
- Bid/Ask
- $3.59 / $3.74
- Market Cap
- $7.28 Mil
- Volume/Avg
- 4,686 / 388,203
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.tenaxthera.com
Valuation
|
Metric
|
TENX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TENX
|
|---|---|
Quick Ratio | 2.73 |
Current Ratio | 3.26 |
Interest Coverage | −320.72 |
Quick Ratio
TENX
Profitability
|
Metric
|
TENX
|
|---|---|
Return on Assets (Normalized) | −66.78% |
Return on Equity (Normalized) | −77.71% |
Return on Invested Capital (Normalized) | −73.88% |
Return on Assets
TENX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dyfvvbfkt | Vvx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Smrdqsfc | Zzpgv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Grbcrtm | Xxdqny | $98.1 Bil | |
MRNA
| Moderna Inc | Vwnbnjwd | Pzqj | $39.1 Bil | |
ARGX
| argenx SE ADR | Djnktxcc | Stzw | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Hwjtkngsf | Tmqq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gbpglskj | Fjlllf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gvkygjvh | Yltyrq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cpjxsvzsx | Bwnnppv | $12.5 Bil | |
INCY
| Incyte Corp | Kmwnhbsm | Lyhwd | $11.9 Bil |